PEMBROLIZUMAB INDUCED PNEUMONITIS EXPERIENCE IN A HOSPITAL OF QUITOECUADOR

María Herrera Herrera, Santiago Almeida Pinto, Christian Aguilar Erazo, Diana Tolagasí Quilumba, Ana Pachacama Barros, Andrés Benavides Zúñiga, Darwin Cortez Palma, Valeria Naranjo Benavides

Abstract


Immunotherapy-induced pneumonitis is a complication present in 3% in patients with non-small cell lung cancer based on this treatment, being the same difficult to diagnose even more in a country that is not in international experience, In this review we want to present our experience with the first patient treated with pembrolizumab in our institution

Full Text:

PDF

References


KADONO T. Immune-related adverse events by immune checkpoint inhibitors. Japanese J Clin Immunol [Internet]. 2017;40(2):83–9. Available from: https://www.jstage.jst.go.jp/article/jsci/40/2/40_83/_article/-char/ja/

Cousin S, Italiano A. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clin Cancer Res [Internet]. 2016 Sep 15;22(18):4550–5. Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-2569

Horio Y. Management of toxicities of immune checkpoint inhibitors. Japanese Journal of Cancer and Chemotherapy. 2017.

Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist [Internet]. 2016 May;21(5):643–50. Available from: http://theoncologist.alphamedpress.org/lookup/doi/10.1634/theoncologist.2015-0498

Ueno R, Nemoto M, Uegami W, Fukuoka J, Misawa M. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation. Respir Med Case Reports [Internet]. 2019;26:168–70. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2213007118303551

Leroy V, Templier C, Faivre J-B, Scherpereel A, Fournier C, Mortier L, et al. Pembrolizumab-induced pneumonitis. ERJ Open Res [Internet]. European Respiratory Society; 2017 Apr 1;3(2):00081-2016. Available from: http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00081-2016

Naidoo J, Page DB, Wolchok JD. Immune Checkpoint Blockade. Hematol Oncol Clin North Am [Internet]. 2014 Jun;28(3):585–600. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889858814000173

Peris BH, Coloma JH, Pérez RAA, Gómez C, Miguel L, Esteve S, et al. NEUMONITIS SECUNDARIA A INHIBIDORES DE PD1 EN PACIENTES CON CARCINOMA NO MICROCÍTICO DE PULMÓN. REVISIÓN A PROPOSITO DE UN CASO. GIDO Post [Internet]. 2017;2:1–9. Available from: https://gido.es/post/2017/08/01/neumonitis-secundaria-a-inhibidores-de-pd1-en-pacientes-con-carcinoma-no-microcitico-de-pulmon-revision-a-proposito-de-un-caso/

Marin-Acevedo JA, Chirila RM, Dronca RS. Immune Checkpoint Inhibitor Toxicities. Mayo Clin Proc [Internet]. 2019 Jul;94(7):1321–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0025619619302757

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol [Internet]. 2016 Apr;27(4):559–74. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv623

Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol [Internet]. 2015 Jun 20;33(18):2092–9. Available from: http://ascopubs.org/doi/10.1200/JCO.2014.60.0379

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;

Leroy V, Templier C, Faivre J-B, Scherpereel A, Fournier C, Mortier L, et al. Pembrolizumab-induced pneumonitis. ERJ Open Res [Internet]. 2017 Apr;3(2):00081-2016. Available from: http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00081-2016

Su Q, Zhu EC, Wu J, Li T, Hou Y, Wang D, et al. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. Front Immunol [Internet]. 2019 Feb 4;10(FEB). Available from: https://www.frontiersin.org/article/10.3389/fimmu.2019.00108/full

Ahn M-J, Gandhi L, Hamid O, Hellmann MD, Garon EB, Ramalingam SS, et al. 459PRisk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001. Ann Oncol [Internet]. 2015 Dec 19;26(suppl 9):ix140.3-ix140. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv532.


Refbacks

  • There are currently no refbacks.